SEC EDGARJUL 81 min read$TBPH

Samaha Eli sold $119K of TBPH (indirect holdings)

Samaha Eli sold 6,964 indirectly-held shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.14 ($17.04–$17.17, $0.12M total) across 2 trades over 2026-07-06 to 2026-07-07.

Original reporting

SEC EDGAR · Samaha Eli

Published Jul 8, 2026, 8:13 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 8, 2026, 8:15 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TBPH

Neutral

medium confidence

Mentioned

$TBPH

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TBPHNeutralLow

Why it matters

The disclosure updates insider ownership and may marginally affect sentiment, but it does not introduce new operational or financial information about TBPH.

Market read

Traders may monitor TBPH for follow-on insider activity, but this specific filing is unlikely to drive a durable repricing without accompanying fundamentals.

What to watch

Because the filing states no pre-arranged 10b5-1 plan, traders may overinterpret intent; also, the remaining holdings are still very large (9,167,489 shares after).

Relevance 4/10Novelty 3/10Timing: Filed after-hours on 2026-07-08, covering sales on 2026-07-06 to 2026-07-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Theravance Biopharma, Inc.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TBPHNeutralMedium confidence

Context

Samaha Eli, a 10% owner, sold 6,964 TBPH shares in open-market trades at about $17.04 to $17.17 per share.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus normal insider-sale noise.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with defined trade dates and value, but it provides no earnings, guidance, trial, or deal catalyst.

Market effects

Sector

No clear sector read-through; this is company-specific insider selling without additional biotech/clinical context.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be diversification or liquidity-driven, especially since the trades were spread across two days and the filing does not cite any negative company development.

Key entities

issuer
Theravance Biopharma, Inc.
Subject of the Form 4 insider sale disclosure.
insider
Samaha Eli
10% owner who sold TBPH shares via open-market transactions.

Read at source ← All news

SEP 28

$ZYMEHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

gurufocus.com3 min

SEP 23

$ZYMEHighAI 8/10

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

finanznachrichten.de2 min

SEP 23

$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min

AUG 10

$TBPHMedAI 8/10

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

tradingview.com2 min

AUG 10

$TBPHHigh

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Revenue increased 11% year-over-year 1 , from $18

SEC EDGAR 8-K6 min

JUL 21

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min